EUVIMEDEUVIMED entdecken
Crossref

Obinutuzumab (Gazyva) for Lupus Nephritis

The Medical Letter on Drugs and Therapeutics · 16.03.2026 · 68 (1750) · 46-47

DOI: 10.58347/tml.2026.1750c ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 16.03.2026.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obinutuzumab (Gazyva – Genentech), a CD20-directed monoclonal antibody, has been approved by the FDA for treatment of adults with active lupus nephritis who are receiving standard treatment. It was previously approved for treatment of chronic lymphocytic leukemia and follicular lymphoma. Obinutuzumab is the third drug to be approved in the US for treatment of lupus nephritis; the oral calcineurin inhibitor voclosporin (Lupkynis) and the parenteral B-lymphocyte stimulator (BlyS)-specific inhibitor belimumab (Benlysta) were approved earlier.

Schlagwörter

Stichwörter der Autor:innen

BenlystaGazyvaLupkynisOcrevusRituxanadverse effectsbelimumabdosageefficacyhydroxychloroquinelupusmycophenolate mofetilobinutuzumabocrelizumabrituximab

Zitieren

APA

(2026). Obinutuzumab (Gazyva) for Lupus Nephritis. The Medical Letter on Drugs and Therapeutics, 68(1750), 46-47. https://doi.org/10.58347/tml.2026.1750c

Vancouver

Obinutuzumab (Gazyva) for Lupus Nephritis. The Medical Letter on Drugs and Therapeutics. 2026;68(1750):46-47. doi:10.58347/tml.2026.1750c

BibTeX
@article{euvimed2026,
  title = {Obinutuzumab (Gazyva) for Lupus Nephritis},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2026},
  volume = {68},
  number = {1750},
  pages = {46--47},
  doi = {10.58347/tml.2026.1750c}
}
Kostenlos starten →